Anupam Rasayan India: Update on disclosure dated 28 September 2026 on the intimation of acquisition of equity shares of Bliss GVS…
Anupam Rasayan India (ANURAS) filed a disclosure titled "Update on disclosure dated 28 September 2026 on the intimation of acquisition of equity shares of Bliss GVS Pharma Limited". The company is valued at about ₹13,445 crore.
What happened
Anupam Rasayan India (ANURAS) filed a disclosure with the exchanges on 30 September 2026 at 06:56 PM titled "Update on disclosure dated 28 September 2026 on the intimation of acquisition of equity shares of Bliss GVS Pharma Limited".
From the filing: "Anupam Rasayan India Limited has informed the Exchange about update on disclosure dated 28 September 2026 on the intimation of acquisition of equity shares of Bliss GVS Pharma Limited"
Company snapshot
Anupam Rasayan India is a small-cap company in the Chemicals sector, with a market value of about ₹13,445 crore.
The stock last traded at ₹1,181, against a 52-week range of ₹1,047.9–₹1,415 (16.5% below the high).
Before this filing the shares had moved −5.8% over the month and −6.6% over three months. Average daily turnover over the last 20 sessions was about ₹68.28 crore.
Promoters held 59.07% at the end of Q1 FY27; 21.79% of promoter shares were pledged. Foreign institutions owned 7.71% and domestic institutions 0.38%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 486 | 34 | 3.1 |
| Q2 FY26 | 731 | 44.4 | 3.93 |
| Q3 FY26 | 512 | 49 | 4.31 |
| Q4 FY26 | 636 | 42.7 | 3.75 |
| Q1 FY27 | 655 | 38.6 | 3.39 |
What history shows
BCEIE's records show 3 previous m&a filings from the company since May 2026.
Across 48 similar disclosures by other Chemicals companies, shares moved −1.2% on average the next day and −1.1% over five days; 31% of them rose the next day.
Market-wide, 1,926 m&a filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 50% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
In the news
Recent coverage elsewhere (links open the original publisher):
- Anupam Rasayan Completes Purchase of 48.2% Stake in Bliss GVS Pharma for Rs 1,750 Cr
- Anupam Rasayan completes Bliss GVS deal, targets Rs 4,000-crore integrated platform
- Surat-based Anupam Rasayan completes ₹1,750-cr acquisition of 48.2% in Bliss GVS Pharma
- Anupam Rasayan completes Rs. 1,750 crore acquisition of Bliss GVS Pharma to build global platform
- Anupam Rasayan takes control of Bliss GVS in ₹1,750 crore bet on pharma scale-up
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.